Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial.

Journal Article

BACKGROUND: In the Coronavirus Efficacy (COVE) trial, estimated mRNA-1273 vaccine efficacy against coronavirus disease-19 (COVID-19) was 94%. SARS-CoV-2 antibody measurements were assessed as correlates of COVID-19 risk and as correlates of protection. METHODS: Through case-cohort sampling, participants were selected for measurement of four serum antibody markers at Day 1 (first dose), Day 29 (second dose), and Day 57: IgG binding antibodies (bAbs) to Spike, bAbs to Spike receptor-binding domain (RBD), and 50% and 80% inhibitory dilution pseudovirus neutralizing antibody titers calibrated to the WHO International Standard (cID50 and cID80). Participants with no evidence of previous SARS-CoV-2 infection were included. Cox regression assessed in vaccine recipients the association of each Day 29 or 57 serologic marker with COVID-19 through 126 or 100 days of follow-up, respectively, adjusting for risk factors. RESULTS: Day 57 Spike IgG, RBD IgG, cID50, and cID80 neutralization levels were each inversely correlated with risk of COVID-19: hazard ratios 0.66 (95% CI 0.50, 0.88; p=0.005); 0.57 (0.40, 0.82; p=0.002); 0.42 (0.27, 0.65; p<0.001); 0.35 (0.20, 0.61; p<0.001) per 10-fold increase in marker level, respectively, multiplicity adjusted P-values 0.003-0.010. Results were similar for Day 29 markers (multiplicity adjusted P-values <0.001-0.003). For vaccine recipients with Day 57 reciprocal cID50 neutralization titers that were undetectable (<2.42), 100, or 1000, respectively, cumulative incidence of COVID-19 through 100 days post Day 57 was 0.030 (0.010, 0.093), 0.0056 (0.0039, 0.0080), and 0.0023 (0.0013, 0.0036). For vaccine recipients at these titer levels, respectively, vaccine efficacy was 50.8% (-51.2, 83.0%), 90.7% (86.7, 93.6%), and 96.1% (94.0, 97.8%). Causal mediation analysis estimated that the proportion of vaccine efficacy mediated through Day 29 cID50 titer was 68.5% (58.5, 78.4%). CONCLUSIONS: Binding and neutralizing antibodies correlated with COVID-19 risk and vaccine efficacy and likely have utility in predicting mRNA-1273 vaccine efficacy against COVID-19. TRIAL REGISTRATION NUMBER: COVE number, NCT04470427.

Full Text

Duke Authors

Cited Authors

  • Gilbert, PB; Montefiori, DC; McDermott, A; Fong, Y; Benkeser, D; Deng, W; Zhou, H; Houchens, CR; Martins, K; Jayashankar, L; Castellino, F; Flach, B; Lin, BC; O'Connell, S; McDanal, C; Eaton, A; Sarzotti-Kelsoe, M; Lu, Y; Yu, C; Borate, B; van der Laan, LWP; Hejazi, N; Huynh, C; Miller, J; El Sahly, HM; Baden, LR; Baron, M; De La Cruz, L; Gay, C; Kalams, S; Kelley, CF; Kutner, M; Andrasik, MP; Kublin, JG; Corey, L; Neuzil, KM; Carpp, LN; Pajon, R; Follmann, D; Donis, RO; Koup, RA

Published Date

  • August 15, 2021

Published In

  • Medrxiv

PubMed ID

  • 34401888

Pubmed Central ID

  • PMC8366808

Digital Object Identifier (DOI)

  • 10.1101/2021.08.09.21261290


  • eng

Conference Location

  • United States